ARTICLE | Clinical News

Erbitux cetuximab regulatory update

September 19, 2005 7:00 AM UTC

Health Canada approved Erbitux in combination with irinotecan to treat epidermal growth factor receptor ( EGFR)-expressing, metastatic colorectal cancer who are refractory to other irinotecan-based chemotherapy, and as a single agent therapy for patients who are intolerant to irinotecan-based chemotherapy. ...